Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria

• Main Authors: Yixiang Xu (Author), Chao Zhang (Author), Kai Jiang (Author), Xinchun Yang (Author), Feng Chen (Author), Zhiyang Cheng (Author), Jinlong Zhao (Author), Jiaxing Cheng (Author), Xiaokang Li (Author), Xin Chen (Author), Luoyifan Zhou (Author), Hao Duan (Author), Yunyuan Huang (Author), Yaozu Xiang (Author), Jian Li (Author)
• Format: Book
• Published: Elsevier, 2023-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been reapproved for heart failure (HF) therapy in patients with and without diabetes. However, the initial glucose-lowering indication of SGLT2i has impeded their uses in cardiovascular clinical practice. A challenge of SGLT2i then becomes how t...